AdAlta Limited (ASX:1AD)

Market Cap	3.86M
Revenue (ttm)	973.02K
Net Income (ttm)	-4.94M
Shares Out	643.22M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,356,141
Average Volume	1,207,078
Open	0.0060
Previous Close	0.0060
Day's Range	0.0060 - 0.0060
52-Week Range	0.0055 - 0.0310
Beta	0.31
RSI	29.52
Earnings Date	May 21, 2025

About AdAlta

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 9
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: 1AD

Financial Performance

In 2024, AdAlta's revenue was 1.74 million, a decrease of -49.91% compared to the previous year's 3.47 million. Losses were -5.38 million, 10.9% more than in 2023.